

# Synthesis and anthelmintic properties of arylquinolines with activity against drug resistant nematodes


Sharon Rossiter<sup>a</sup>, Jean-Marie Peron<sup>b</sup>, Philip J. Whitfield<sup>c</sup>, Keith Jones<sup>a,b\*</sup>

*a. Department of Chemistry, King's College London, Strand, London WC2R 2LS, UK. b. School of Chemical and Pharmaceutical Sciences, Kingston University, Penrhyn Road, Kingston-upon-Thames, Surrey, KT1 2EE, UK. c. Division of Life Sciences, Franklin-Wilkins Building, King's College London, 150 Stamford Street, London SE1 9NN, UK*


This is where the receipt/accepted dates will go; Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT]

**Abstract**—2,4-Disubstituted quinolines with additional substituents in positions 5-8 have been found to have anthelmintic properties. A number of 2,4-dimethoxy-6- or 8-arylquinolines have potent activity against the sheep nematode *Haemonchus contortus*, with LD<sub>99</sub> values of the same order of magnitude as levamisole. These arylquinolines maintain their activity against levamisole, ivermectin and thiabendazole resistant strains of *H contortus*. ©2000 Elsevier Science Ltd. All rights reserved.

Parasitic nematode infections are a continuing threat in both human and animal medicine. The most commonly used classes of drugs to treat such infections are the benzimidazoles such as thiabendazole **1**, imidazo-thiazoles such as levamisole **2**, and avermectins (obtained from the fermentation products of *Streptomyces avermitilis*). There is evidence of emerging resistance to some drugs in the developing world,<sup>1</sup> and in some areas with high agricultural dependence multiple resistance to all of the major drug classes is appearing in livestock.<sup>2</sup> Alternatives to these classes of drug are now being sought.



thiabendazole **1**




levamisole **2**

We recently published a concise synthesis of the prenylquinoline alkaloid atanine, **3**,<sup>3</sup> shown to be active against larval stages of the trematode parasite *Schistosoma mansoni*, the cause of schistosomiasis (bilharzia), a major health issue in developing countries.<sup>4</sup>

As part of our program of synthesis and testing of novel

atanine analogues, we synthesized a number of intermediate trisubstituted quinolines with substituents in ring positions 5-8. Tests against *S. mansoni* larval stages and the model nematode *C. elegans* revealed that some of these intermediates exhibited anti-nematode activity, differing from the pattern of activity against schistosomes.<sup>5</sup>




**3**

From these early biological results, we became interested in aryl-substituted quinolines, and so we set out to investigate the synthesis of these novel 2,4-dimethoxy aryl-substituted quinolines by exploring the Suzuki coupling of 5-, 6-, 7- or 8-bromoquinoline intermediates.

Substituted-2,4-dimethoxyquinolines were synthesized by condensation/cyclization of the appropriate substituted aniline **4** with malonic acid and phosphoryl chloride to give the 2,4-dichloroquinoline **5**, followed

\* Corresponding author. Current address:


by displacement by methoxide ion to give the required quinoline **6** (Scheme 1).<sup>6</sup>



**Scheme 1.** Synthesis of substituted-2,4-dimethoxy-quinolines

For our proposed synthesis of arylquinolines, the bromoquinoline precursors were synthesized. Cyclization of 3-bromoaniline gave a mixture of the 5- and 7-bromoquinolines, which were separable by column chromatography.

The bromo-2,4-dimethoxy-quinolines **7** were then coupled to the required aryl groups under Suzuki conditions to yield the arylquinolines **8** (scheme 2). These proceeded in good yield, although it was observed that 8-bromoquinolines were much more sensitive, requiring stricter oxygen-free reaction conditions to give consistent yields.<sup>8</sup>



**Scheme 2.** Synthesis of arylquinolines via Suzuki coupling


**Table 1:** LD<sub>99</sub> values for compounds **9-16** (substituted at positions 2-8) against *H. contortus*

Compound	R2	R3	R4	R5	R6	R7	R8	LD <sub>99</sub> , μg/mL
<b>9</b> <sup>a</sup>	OMe	Ph	OMe	H	H	H	H	25
<b>10</b>	OMe	H	OMe	Me	H	Me	H	25
<b>11</b> <sup>b</sup>	Cl	H	OMe	H	H	H	H	25
<b>12</b>	OMe	H	OMe	H	Cl	H	H	12.5
<b>13</b>	OMe	H	OMe	H	H	H	Ph	12.5
<b>14</b>	OMe	H	OMe	H	H	H	4-MeO-C <sub>6</sub> H <sub>4</sub>	12.5
<b>15</b>	OMe	H	OMe	H	Ph	H	H	3.1
<b>16</b>	OMe	H	OMe	H	4-MeO-C <sub>6</sub> H <sub>4</sub>	H	H	3.1

<sup>a</sup> Synthesized from 2,4-dimethoxyquinoline by bromination at position 3 and subsequent Suzuki coupling.<sup>5,10</sup>

<sup>b</sup> Product of incomplete substitution of 2,4-dichloroquinoline by methoxide

A number of 2,4-disubstituted quinolines (*ca* 80) were tested against the agriculturally important parasitic nematode *Haemonchus contortus*, using the commercial NemaTox larval development screen used for determining drug susceptibility.<sup>9</sup> It was observed that greater than 40% of these compounds exhibited nematocidal activity (LD<sub>99</sub> <100 μg/mL), with those exhibiting LD<sub>99</sub> better than 25 μg/mL shown in Table 1. In particular, it appeared that 6- or 8-substituted 2,4-dimethoxyquinolines showed the greatest activity against *H. contortus*. Five compounds, including the arylquinolines **13-16**, had LD<sub>99</sub> of 12.5 μg/mL or lower in this first screen, showing potential for useful anti-nematode activity. The LD<sub>99</sub> of compounds **15** and **16**, 3.1 μg/mL, was of the same order as the commercial nematocides levamisole and closantel. These five most active compounds were resynthesized in gram quantities for further investigation.



**Table 2:** LD<sub>99</sub> values of compounds **12-16** against susceptible and drug-resistant nematodes

Compound	LD <sub>99</sub> , µg/mL					
	<i>H. contortus</i> susceptible	<i>H. contortus</i> VSRG, benzimidazole resistant	<i>H. contortus</i> Lawes, levamisole and benzimidazole resistant	<i>H. contortus</i> CAVR, ivermectin resistant	<i>T. colubriformis</i>	<i>O. circumcincta</i>
12	13	13	8.8	6.3	25	13
13	6.3	4.4	6.3	3.1	50	6.3
14	6.3	6.3	3.1	3.1	6.3	3.1
15	3.1	3.1	3.1	3.1	6.3	3.1
16	3.1	2.2	1.6	1.6	3.1	3.1
1	0.16	5	5	0.16	nt	nt
2	1.6	1.6	>100	0.78	nt	nt

nt: not tested

Compounds **12-16** were tested against susceptible strains of *H. contortus*, strains resistant to benzothiazoles (VSRG strain), ivermectin (CAVR strain) or both benzothiazoles and levamisole (Lawes strain), plus susceptible strains of *T. colubriformis* and *O. circumcincta*. Results are shown in Table 2, with activities of thiabendazole **1** and levamisole **2** for comparison.

Of these compounds, **15** and **16** exhibited the greatest activity against susceptible strains of *H. contortus* (3.1 µg/mL), comparable in potency to levamisole. **15** and **16** were also potent against the various drug-resistant strains of *H. contortus*, with even improved activity for **16**; LD<sub>99</sub> 1.6 µg/mL, against both the multiple-resistant Lawes strain and the ivermectin resistant CAVR strain. There is also evidence of activity against the important parasitic nematodes *Trichostrongylus colubriformis* and *Ostertagia circumcincta*.

In summary, we have prepared novel arylquinolines in good yields via Suzuki coupling of substituted bromoquinolines. We have demonstrated that a number of these quinolines, in particular the 6-arylquinolines **15**, **16**, show promising potency against susceptible and drug-resistant strains of an important nematode target, and represent a new class of anthelmintic compounds. There is obvious potential for lead optimization and further development to offer a new line of defence against drug-resistant parasitic nematode infections.

**Acknowledgements.** This work was supported by a Wellcome Trust studentship (SR). The authors thank Schering-Plough Animal Health for arranging the biological testing.

## References and notes

- Albonico, M.; Bickle, Q.; Ramsan, M.; Montresor, A.; Savioli, L.; Taylor, M. *Bull. World Health Organiz.* **2003**, *81*, 343-352
- (a) Besier, R.B.; Love, S.C.J. *Aust. J. Exp. Agr.* **2003**, *43*, 1383-1391. (b) Thomaz-Soccol, V.; de Souza, F.P.; Sotomaior, C.; Castro, E.A.; Milczewski, V.; Mocelin, G.; Silva, M.D.C.P.E. *Braz. Arch. Biol. Technol.* **2004**, *47*, 41-47.
- Jones, K.; Roset, X.; Rossiter, S.; Whitfield, P.J.; *Org. Biomol. Chem.* **2003**, *1*, 4380-4383.
- Perrett, S.; Whitfield, P. J. *Planta Medica* **1995**, *61*, 276-278
- Rossiter, S. Ph.D. thesis, University of London, 1999.
- Ziegler, E.; Gelfert, K. *Monatsh. Chem.* **1959**, *90*, 822-826
- Miyaura, N.; Suzuki, A. *Chem. Rev.* **1995**, *95*, 2457-2483
- Synthesis of arylquinolines: typical procedure: 8-Bromo-2,4-dimethoxyquinoline (0.4 g, 1.5 mmol) was dissolved in toluene (10 mL) under argon. Tetrakis-(triphenylphosphine)palladium (0) (52 mg, 3 mol%) and aqueous sodium carbonate (2 mL of a 2M solution) were added, and the mixture stirred for 5 minutes. Benzeneboronic acid (0.20 g, 1.7 mmol) in ethanol (1 mL) was added, and the mixture was then heated under reflux for 48 hours. After cooling, the mixture was poured into a separating funnel, and the reaction flask washed with water (20 mL) and ether (20 mL); the washings being added to the separating funnel. The aqueous layer was extracted with ether (3 × 20 mL), and the combined organic layers were dried over magnesium sulfate before removal of the solvent under reduced pressure. The crude product was purified by column chromatography (9:1 hexane:EtOAc) to yield 90% of the title compound as white plates, mpt. (CH<sub>2</sub>Cl<sub>2</sub>/MeOH) 110-112 °C; found M<sup>+</sup>: 265.1105, C<sub>17</sub>H<sub>15</sub>NO<sub>2</sub> requires 265.1103; <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.16 (1H, dd, *J* 8.2, 1.5 Hz, H5), 7.90 (2H, dd, *J* 8.3, 1.5 Hz, H2', H6'), 7.77 (1H, dd, *J* 7.2, 1.5 Hz, H7), 7.54 (2H, m, H6 and H4'), 7.47 (2H, dd, *J* 8.3, 7.2 Hz, H3', H5'), 6.29 (1H, s, H3), 4.01

(3H, s, OMe), 3.99 (3H, s, OMe); ; <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.5, 163.4 (C2, C4), 144.7, 140.4, 138.5 (C1', C8, C8a), 131.3, 131.1, 127.9, 127.2, 123.5, 121.8 (C5, C6, C7, C2'-6'), 120.1 (C4a), 90.7 (C3), 56.2 (OMe), 53.8 (OMe); anal. found C 76.91, H 5.65, N 5.19%, calculated for C<sub>17</sub>H<sub>15</sub>NO<sub>2</sub> C 76.96, H 5.70, N 5.28%;

9. (a) Lacey E.; Redwin, J.M.; Gill, J.H.; Demargheriti, V.M.; Waller, P.J. in *Resistance of Parasites to Antiparasitic Drugs*, MSD AGVET, Rahway, NJ, USA, pp177-184. (b) NemaTox assay: 80 to 100 nematode eggs were added to each well of a multiwell plate containing the compound under investigation (at a range

of concentrations from 100 ug/mL downwards in sequential twofold dilutions) in an agar matrix. The wells were supplemented with nutrient medium and incubated at 26°C until larvae in the control wells had developed to the 1.3 larval stage. On Day 5, a qualitative assessment of the larvae was performed to determine the lowest concentration at which development was inhibited in 99% of the larvae present.

10. Stavenulier, J.; Hamzink, M.; van der Hulst, R.; Zomer, G.; Westra, G.; Kriek, E. *Heterocycles* **1987**, *10*, 2711-2716.